Improvement in symptoms of peripheral arterial disease with sildenafil therapy

Scottish Medical Journal

Volumn 58, Issue 3, 2013, Pages

  Turtle, E J ^a   Drummond, I D ^a   Webb, D J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Nitric oxide; Peripheral arterial disease; Phosphodiesterase type 5 inhibitors; Sildenafil

Indexed keywords

SILDENAFIL; SIMVASTATIN;

ADULT; ARTICLE; CASE REPORT; ERECTILE DYSFUNCTION; HUMAN; INTERMITTENT CLAUDICATION; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; SMOKING; SYMPTOM; WALKING;

NITRIC OXIDE; PERIPHERAL ARTERIAL DISEASE; PHOSPHODIESTERASE TYPE-5 INHIBITORS; SILDENAFIL;

ANTICHOLESTEREMIC AGENTS; ERECTILE DYSFUNCTION; EXERCISE THERAPY; HUMANS; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; SCOTLAND; SIMVASTATIN; SULFONES; TREATMENT OUTCOME; WALKING;

EID: 84890247512     PISSN: 00369330     EISSN: None     Source Type: Journal    
DOI: 10.1177/0036933013496919     Document Type: Article

References (19)

1. Sildenafil. http://en.wikipedia.org/wiki/Sildenafil (accessed 1 July 2013)
2. Lue TF. Erectile dysfunction. N Engl J Med 2000; 342: 1802-1813
3. Gingell C, Sultana SR, Wulff MB, et al. Duration of action of sildenafil citrate in men with erectile dysfunction. J Sex Med 2004; 1: 179-184
4. Saenz de Tejada I, Angulo J, Cuevas P, et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001; 13: 282-290
5. Eardley I and Cartledge J. Tadalafil (Cialis) for men with erectile dysfunction. Int J Clin Pract 2002; 56: 300-304
6. Archer SL and Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med 2009; 361: 1864-1871
7. Oliver JJ, Melville VP and Webb DJ. Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension 2006; 48: 622-627
8. Wolk R, Smith WB, Neutel JM, et al. Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension. Hypertension 2009; 53: 1091-1097
9. Oliver JJ, Dear JW and Webb DJ. Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension. Hypertension 2010; 56: 62-67
10. Grover-Páez F, Villegas Rivera G and Guillén Ortíz RO. Sildenafil citrate diminishes microalbuminuria and the percentage of A1c in male patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 78: 136-140
11. Schwartz BG, Levine LA, Comstock G, et al. Cardiac uses of phosphodiesterase-5 inhibitors. J Am Coll Cardiol 2012; 59: 9-14
12. Olin JW and Sealove BA. Peripheral artery disease: current insights into the disease and its diagnosis and management. Mayo Clin Pro 2010; 85: 678-692
13. Fowkes FG, Housley E, Cawood EH, et al. Edinburgh artery study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991; 20: 384-392
14. Kannel WB, Skinner JJ, Schwartz MJ, et al. Intermittent claudication. Incidence in the Framingham study. Circulation 1970; 41: 875-883
15. Park KB, Do YS, Kim DI, et al. The TransAtlantic InterSociety consensus (TASC) classification system in iliac arterial stent placement: long-term patency and clinical limitations. J Vasc Interv Radiol 2007; 18: 193-201
16. Boger RJ, Bode-Boger SM, Thiele W, et al. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997; 95: 2068-2074
17. Bode-Böger SM, Böger RH, Alfke H, et al. L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study. Circulation 1996; 93: 85-90
18. Senthilkumar A, Smith RD, Khitha J, et al. Sildenafil produces ischemia-induced angiogenesis through a PKG-dependent pathway. Arterioscler Thromb Vasc Biol 2007; 27: 1947-1954
19. Sahara M, Sata M, Morita T, et al. A phosphodiesterase- 5 inhibitor vardenafil enhances angiogenesis through a protein kinase G-dependent hypoxia-inducible factor -1/ vascular endothelial growth factor pathway. Arterioscler Thromb Vasc Biol 2010; 30: 1315-1324.